Angiotensin receptor blockers reduce left ventricular hypertrophy in dialysis patients: A meta-analysis

American Journal of the Medical Sciences

Volumn 345, Issue 1, 2013, Pages 1-9

  Yang, Li Ya ^a   Ge, Xiao ^a   Wang, Yan Li ^a   Ma, Kun Ling ^a   Liu, Hong ^a   Zhang, Xiao Liang ^a   Liu, Bi Cheng ^a  

^a MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

Author keywords

Angiotensin receptor blocker; Dialysis; Left ventricular function; Left ventricular hypertrophy; Meta analysis

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPROSARTAN; IRBESARTAN; LOSARTAN; PLACEBO; TELMISARTAN; VALSARTAN;

HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEMODIALYSIS PATIENT; HUMAN; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

EID: 84871985675     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e318249d387     Document Type: Article

References (49)

1. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-305.
2. Heerspink HJ, Ninomiya T, Zoungas S, et al. Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. Lancet 2009;373:1009-15.
3. Koren MJ, Devereux RB, Casale PN, et al. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991;114:345-52.
4. Mensah GA, Pappas TW, Koren MJ, et al. Comparison of classification of the severity of hypertension by blood pressure level and by World Health Organization criteria in the prediction of concurrent cardiac abnormalities and subsequent complications in essential hypertension. J Hypertens 1993;11:1429-40.
5. Ghali JK, Liao Y, Simmons B, et al. The prognostic role of left ventricular hypertrophy in patients with or without coronary artery disease. Ann Intern Med 1992;117:831-6.
6. Bikkina M, Levy D, Evans JC, et al. Left ventricular mass and risk of stroke in an elderly cohort: The Framingham Heart Study. JAMA 1994; 272:33-6.
7. Levy D, Garrison RJ, Savage DD, et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990;322:1561-6.
8. Devereux RB, Alderman MH. Role of preclinical cardiovascular disease in the evolution from risk factor exposure to development of morbid events. Circulation 1993;88:1444-55.
9. Foley RN, Parfrey PS, Harnett JD, et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 1995;47:186-92.
10. Silberberg JS, Barre PE, Prichard SS, et al. Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int 1989;36: 286-90.
11. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998;32: S112-9.
12. Gjata M, Nelaj E, Collaku L, et al. Left ventricular hypertrophy in chronic kidney disease. Is pulse pressure an independent risk factor. Med Arh 2011;65:30-1.
13. Al-Hilali N, Hussain N, Ataia AI, et al. Hypertension and hyperparathyroidism are associated with left ventricular hypertrophy in patients on hemodialysis. Indian J Nephrol 2009;19:153-7.
14. Movilli E, Viola BF, Brunori G, et al. Long-term effects of arteriovenous fistula closure on echocardiographic functional and structural findings in hemodialysis patients: a prospective study. Am J Kidney Dis 2010;55:682-9.
15. Foley RN, Parfrey PS, Harnett JD, et al. Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease. Kidney Int 1996;49:1379-85.
16. Zoccali C, Mallamaci F, Tripepi G, et al. Prediction of left ventricular geometry by clinic, pre-dialysis and 24-h ambulatory BP monitoring in hemodialysis patients: CREED investigators. J Hypertens 1999;17:1751-8.
17. Agarwal R, Sinha AD. Cardiovascular protection with antihypertensive drugs in dialysis patients: systematic review and meta-analysis. Hypertension 2009;53:860-6.
18. Inaba S, Iwai M, Furuno M, et al. Temporary treatment with AT1 receptor blocker, valsartan, from early stage of hypertension prevented vascular remodeling. Am J Hypertens 2011;24:550-6.
19. Barrios V, Calderón A, Escobar C, et al. Electrocardiographic left ventricular hypertrophy regression induced by an angiotensin receptor blocker-based regimen in daily clinical practice: the SARA study. J Hypertens 2007;25:1967-73.
20. Suzuki H, Kanno Y, Kaneko K, et al. Comparison of the effects of angiotensin receptor antagonist, angiotensin converting enzyme inhibitor, and their combination on regression of left ventricular hypertrophy of diabetes type 2 patients on recent onset hemodialysis therapy. Ther Apher Dial 2004;8:320-7.
21. Shibasaki Y, Nishiue T,Masaki H, et al. [Angiotensin II type 1 antagonist suppress left ventricular hypertrophy and myocardial fibrosis in patient with end stage renal disease (ESRD)]. Nippon Rinsho 2002;60:1992-8.
22. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12.
23. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924-6.
24. Brookes ST, Whitley E, Peters TJ, et al. Subgroup analyses in randomized controlled trials: quantifying the risks of false-positives and false-negatives. Health Technol Assess 2001;5:1-56.
25. Kanno Y, Kaneko K, Kaneko M, et al. Angiotensin receptor antagonist regresses left ventricular hypertrophy associated with diabetic nephropathy in dialysis patients. J Cardiovasc Pharmacol 2004;43:380-6.
26. Suzuki H, Nakamoto H, Okada H, et al. A selective angiotensin receptor antagonist, Valsartan, produced regression of left ventricularhypertrophy associated with a reduction of arterial stiffness. Adv Perit Dial 2003;19:59-66.
27. Shigenaga A, Tamura K, Dejima T, et al. Effects of angiotensin II type 1 receptor blocker on blood pressure variability and cardiovascular remodeling in hypertensive patients on chronic peritoneal dialysis. Nephron Clin Pract 2009;112:c31-40.
28. Mitsuhashi H, Tamura K, Yamauchi J, et al. Effect of losartan on ambulatory short-term blood pressure variability and cardiovascular remodeling in hypertensive patients on hemodialysis. Atherosclerosis 2009;207:186-90.
29. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-906.
30. Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigtors. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75.
31. Takahashi A, Takase H, Toriyama T, et al. Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis - a randomized study. Nephrol Dial Transplant 2006;21:2507-12.
32. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.
33. Zoccali C, Benedetto FA, Mallamaci F, et al. Prognostic impact of the indexation of left ventricular mass in patients undergoing dialysis. J Am Soc Nephrol 2001;12:2768-74.
34. Collins AJ, Foley R, Herzog C, et al. Excerpts from the United States Renal Data System 2007 annual data report. Am J Kidney Dis 2008;51: S1-320.
35. Malmqvist K, Kahan T, Edner M, et al. Regression of left ventricular hypertrophy in human hypertension with irbesartan. J Hypertens 2001; 19:1167-76.
36. Ogihara T, Fujimoto A, Nakao K, et al. ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial. Expert Rev Cardiovasc Ther 2008;6:1195-201.
37. Devereux RB, Dahlöf B, Gerdts E, et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation 2004;110:1456-62.
38. Fagard RH, Celis H, Thijs L, et al. Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studies. Hypertension 2009;54:1084-91.
39. Li H, Wang SX. Improvement of hypertension and LVH in maintenance hemodialysis patients treated with sustained-release isosorbide mononitrate. J Nephrol 2011;24:236-45.
40. Tai DJ, Lim TW, James MT, et al. Cardiovascular effects of angiotensin converting enzyme inhibition or angiotensin receptor blockade in hemodialysis: a meta-analysis. Clin J Am Soc Nephrol 2010;5: 623-30.
41. Fang W, Oreopoulos DG, Bargman JM. Use of ACE inhibitors or angiotensin receptor blockers and survival in patients on peritoneal dialysis. Nephrol Dial Transplant 2008;23:3704-10.
42. Kolesnyk I, Struijk DG, Dekker FW, et al. Effects of angiotensinconverting enzyme inhibitors and angiotensin II receptor blockers in patients with chronic kidney disease. Neth J Med 2010;68:15-23.
43. Li XF, Charnock-Jones DS, Zhang E, et al. Angiogenic growth factor messenger ribonucleic acids in uterine natural killer cells. J Clin EndocrinolMetab 2001;86:1823-34.
44. Kaschina E, Unger T. Angiotensin AT1/AT2 receptors: regulation, signalling and function. Blood Press 2003;12:70-88.
45. Maejima Y, Okada H, Haraguchi G, et al. Telmisartan, a unique ARB, improves left ventricular remodeling of infarcted heart by activating PPAR gamma. Lab Invest 2011;91:932-44.
46. Pan ZK, Zuraw BL, Lung CC, et al. Bradykinin stimulates NF-kappaB activation and interleukin 1beta gene expression in cultured human fibroblasts. J Clin Invest 1996;98:2042-9.
47. Brown NJ, Gainer JV, Murphey LJ, et al. Bradykinin stimulates tissue plasminogen activator release from human forearm vasculature through B(2) receptor-dependent, NO synthase-independent, and cyclooxygenase- independent pathway. Circulation 2000;102:2190-6.
48. Chan KE, Ikizler TA, Gamboa JL, et al. Combined angiotensinconverting enzyme inhibition and receptor blockade associate with increased risk of cardiovascular death in hemodialysis patients. Kidney Int 2011;80:978-85.
49. Matchar DB, McCrory DC, Orlando LA, et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med 2008;148:16-29.